| Citation: |
ZHAO Lingying, ZHANG Wenqing, LI Cunxi, HU Tianhui. Research Progress on Antitumor Mechanism of Apatinib[J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 7-11. DOI: 10.3971/j.issn.1000-8578.2021.20.0302
|
In recent years, antiangiogenic drugs based on VEGF and VEGFRs signaling pathway have been widely used in the treatment of malignant tumors. Apatinib is an orally bioavailable small-molecule antiangiogenic agent and can specifically inhibit the tyrosine kinase activity of VEGFR, thereby inhibiting tumor angiogenesis. Apatinib is the first-level recommendation of third-line treatment of gastric cancer in CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer published in 2018. Apatinib has been proved to be effective and safe in gastric, lung and breast cancers. In addition, the drug shows great potential in the treatment of a variety of solid tumors. This article reviews the recent progress on the mechanism, clinical efficacy, related efficacy predictors of apatinib and its combination with other antitumor drugs.
| [1] |
Scott LJ. Apatinib: A review in advanced gastric cancer and other advanced cancers[J]. Drugs, 2018, 78(7): 747-758. doi: 10.1007/s40265-018-0903-9
|
| [2] |
Sun H, Zhu MS, Wu WR, et al. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out[J]. World J Hepatol, 2014, 6(12): 830-835. doi: 10.4254/wjh.v6.i12.830
|
| [3] |
Zhang Q, Xiang W, Yi DY, et al. Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas[J]. Stem Cell Res Ther, 2018, 9(1): 228. doi: 10.1186/s13287-018-0977-z
|
| [4] |
Qin S, Li A, Yi M, et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy[J]. J Hematol Oncol, 2019, 12(1): 27. doi: 10.1186/s13045-019-0718-5
|
| [5] |
Zhou Y, Tang F, Wang Y, et al. Advanced alveolar soft part sarcoma responds to apatinib[J]. Oncotarget, 2017, 8(30): 50314-50322. doi: 10.18632/oncotarget.18599
|
| [6] |
Siemann DW, Chaplin DJ, Horsman MR. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer[J]. Cancer Invest, 2017, 35(8): 519-534. doi: 10.1080/07357907.2017.1364745
|
| [7] |
Karasic TB, Rosen MA, O'Dwyer PJ. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?[J]. Cancer Chemother Pharmacol, 2017, 80(4): 661-671. doi: 10.1007/s00280-017-3389-3
|
| [8] |
Peng Y, Cui H, Liu Z, et al. Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report[J]. Onco Targets Ther, 2017, 10: 2289-2295. doi: 10.2147/OTT.S130990
|
| [9] |
Liu KS, Ren TT, Huang Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma[J]. Cell Death Disease, 2017, 8(8): e3015. doi: 10.1038/cddis.2017.422
|
| [10] |
Zheng BX, Ren TT, Huang Y, et al. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3[J]. Biochem Biophys Res Commun, 2018, 495(2): 1695-1701. doi: 10.1016/j.bbrc.2017.12.032
|
| [11] |
Liu ZJL, Zhou YJ, Ding RL, et al. In vitro and in vivo apatinib inhibits vasculogenic mimicry in melanoma MUM-2B cells[J]. PLos One, 2018, 13(7): e0200845. doi: 10.1371/journal.pone.0200845
|
| [12] |
Cheng X, Feng HR, Wu HX, et al. Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer[J]. Cancer Lett, 2018, 431: 105-114. doi: 10.1016/j.canlet.2018.05.046
|
| [13] |
Zhou K, Zhang JW, Wang QZ, et al. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice[J]. Acta Pharmacol Sin, 2019, 40(4): 556-562. doi: 10.1038/s41401-018-0058-y
|
| [14] |
Li XJ, Xu AJ, Li HH, et al. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells. Biochimica Et Biophysica Acta-Molecular Basis of Disease[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(5 Pt A): 1693-1701. doi: 10.1016/j.bbadis.2018.02.014
|
| [15] |
Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma[J]. Cancer Med, 2018, 7(9): 4570-4583. doi: 10.1002/cam4.1664
|
| [16] |
Feng HR, Cheng X, Kuang J, et al. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer[J]. Cell Death Dis, 2018, 9(10): 1030. doi: 10.1038/s41419-018-1054-3
|
| [17] |
Jin Z, Cheng X, Feng H, et al. Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3beta/ANG Signaling Pathway in Anaplastic Thyroid Cancer[J]. Cell Physiol Biochem, 2017, 44(4): 1471-1484. doi: 10.1159/000485583
|
| [18] |
Wang C, Jiang M, Hou H, et al. Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma[J]. Oncol Lett, 2018, 16(5): 5607-5614. doi: 10.3892/ol.2018.9355
|
| [19] |
Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stageⅢ/Ⅳ) non-small cell lung cancer (NSCLC)[J]. Cancer Treat Rev, 2013, 39(3): 252-260. doi: 10.1016/j.ctrv.2012.05.003
|
| [20] |
Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase Ⅱ trial[J]. J Clin Oncol, 2013, 31(26): 3219-3225. doi: 10.1200/JCO.2013.48.8585
|
| [21] |
Hu X, Cao J, Hu W, et al. Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14: 820. doi: 10.1186/1471-2407-14-820
|
| [22] |
Wang Y, Deng MM, Chen QW, et al. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway[J]. Eur J Pharmacol, 2019, 843: 145-153. doi: 10.1016/j.ejphar.2018.11.012
|
| [23] |
Wu D, Liang L, Nie L, et al. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC[J]. Asia Pac J Clin Oncol, 2018, 14(6): 446-452. doi: 10.1111/ajco.12870
|
| [24] |
Wu F, Zhang S, Xiong A, et al. A Phase Ⅱ Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer[J]. Clin Lung Cancer, 2018, 19(6): e831-e842. doi: 10.1016/j.cllc.2018.06.002
|
| [25] |
Liu Z, Chen J, Fang Y, et al. The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study[J]. J Cancer, 2018, 9(16): 2773-2777. doi: 10.7150/jca.26376
|
| [26] |
Du X, Chen D, Lin Z, et al. Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: a retrospective, multicenter study[J]. J BUON, 2019, 24(5): 1956-1963. https://www.researchgate.net/publication/337680664_Efficacy_of_apatinib_in_advanced_hepatocellular_carcinoma_with_lung_metastasis_a_retrospective_multicenter_study
|
| [27] |
Li Q, Qin SK, Gu SZ, et al. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase Ⅲ study[J]. J Clin Oncol, 2020, 38(15suppl): abstr 4507. doi: 10.1200/JCO.2020.38.15_suppl.4507
|
| [28] |
Xie L, Xu J, Sun X, et al. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase Ⅱ Clinical Trial[J]. Oncologist, 2019, 24(7): e542-e550. doi: 10.1634/theoncologist.2018-0542
|
| [29] |
Liu JY, BR Zhu, YD Wang, et al. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis[J]. Int J Clin Oncol, 2020, 25(6): 1195-1205.. doi: 10.1007/s10147-020-01644-7
|
| [30] |
张靖宇, 蒋华, 朱明珍, 等.阿帕替尼治疗晚期肺癌的疗效及疗效预测因子分析[J].实用医学杂志, 2017, 33(22): 3845-3846. doi: 10.3969/j.issn.1006-5725.2017.22.044
Zhang JY, Jiang H, Zhu MZ, et al. Efficacy and efficacy predicator indicative factors of Aptinib in patients with advanced lung cancer[J]. Shi Yong Yi Xue Za Zhi, 2017, 33(22): 3845-3846. doi: 10.3969/j.issn.1006-5725.2017.22.044
|
| [31] |
Chen Z, Huang W, Tian T, et al. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer[J]. J Hematol Oncol, 2018, 11(1): 20. doi: 10.1186/s13045-018-0563-y
|
| [32] |
Fang SC, Huang W, Zhang YM, et al. Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib[J]. Onco Targets Ther, 2019, 12: 985-992. doi: 10.2147/OTT.S189984
|
| [33] |
Wang D, Lin J, Yang X, et al. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies[J]. J Hematology Oncol, 2019, 12(1): 42. doi: 10.1186/s13045-019-0730-9
|
| [34] |
Zhao S, Ren S, Tao J, et al. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer[J]. Cancer Immunol Res, 2019, 7(4): 630-643. doi: 10.1158/2326-6066.CIR-17-0640
|
| [35] |
Xu J, Zhang Y, Jia R, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study[J]. Clin Cancer Res, 2019, 25(2): 515-523. doi: 10.1158/1078-0432.CCR-18-2484
|
| [36] |
Cui CL, Zhou L, Lian B, et al. Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure[J]. Transl Oncol, 2018, 11(5): 1155-1159. doi: 10.1016/j.tranon.2018.07.009
|
| [37] |
Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial[J]. Cancer Biol Ther, 2017, 18(6): 433-438. doi: 10.1080/15384047.2017.1323589
|
| [38] |
Lan CY, Wang Y, Xiong Y. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study (vol 19, pg 1239, 2018)[J]. Lancet Oncol, 2018, 19(9): 1239-1246. doi: 10.1016/S1470-2045(18)30349-8
|
| [1] | ZHAO Qian, LI Feng. Role and Research Progress of CD81 in Tumors[J]. Cancer Research on Prevention and Treatment, 2025, 52(3): 233-240. DOI: 10.3971/j.issn.1000-8578.2025.24.0730 |
| [2] | WANG Hao, JIN Yan, WU Nan. Advances in Research Methods of Tumor Angiogenesis[J]. Cancer Research on Prevention and Treatment, 2023, 50(7): 721-725. DOI: 10.3971/j.issn.1000-8578.2023.23.0070 |
| [3] | WU Daichao, CHEN Lin, CHEN Yongheng, CHEN Zhuchu. Research Progress of FGFR4 Targeted Anti-tumor Drug[J]. Cancer Research on Prevention and Treatment, 2017, 44(1): 61-65. DOI: 10.3971/j.issn.1000-8578.2017.01.013 |
| [4] | ZHANG Xu, XU Meng, LIU Ye, GU Xiaoxiao, QIAN Hui, XU Wenrong. Role of Nanog in Tumorigenesis and Tumor Development[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 295-299. DOI: 10.3971/j.issn.1000-8578.2016.04.012 |
| [5] | LIU Chang, WANG Xie, SHEN Lijuan. Subcelluar Localization of p27kip1 and Tumour[J]. Cancer Research on Prevention and Treatment, 2015, 42(05): 522-525. DOI: 10.3971/j.issn.1000-8578.2015.05.022 |
| [6] | XIAO Bing, YE Minhua, ZHU Xingen. Advances of IKKε in Tumor[J]. Cancer Research on Prevention and Treatment, 2015, 42(01): 69-73. DOI: 10.3971/j.issn.1000-8578.2015.01.017 |
| [7] | SUN Peng, WANG Yanlin. Tumor-associated Macrophages Development and Treatment of Tumor[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 829-833. DOI: 10.3971/j.issn.1000-8578.2014.07.031 |
| [8] | LI Yan-kui, ZHANG Xiao-ming, SHEN Chen-yang, LI Qing-le, CHEN Jian-qiu. Surgical Treatment of Tumor Invading Vital Vessels[J]. Cancer Research on Prevention and Treatment, 2010, 37(09): 1062-1063. DOI: 10.3971/j.issn.1000-8578.2010.09.023 |
| [9] | HE Xusheng, WANGJian-hua, DIAO Sheng-lin. CT Study on Parotid Tumors[J]. Cancer Research on Prevention and Treatment, 2005, 32(03): 164-165. DOI: 10.3971/j.issn.1000-8578.2480 |
| [10] | Pen GuiYoug, . Study on transfer factor in killing and inhibiting tumor cells[J]. Cancer Research on Prevention and Treatment, 1994, 21(6): 360-361. |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: